This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Announces Full-Year And Fourth-Quarter 2012 Financial Results

Select Revenue Highlights

Full-year 2012 worldwide sales were $47.3 billion, a decrease of 2 percent, which includes a 3 percent negative impact from foreign exchange, compared to full-year 2011. Worldwide sales were $11.7 billion for the fourth quarter of 2012, a decrease of 5 percent, which includes a 2 percent negative impact from foreign exchange compared with the fourth quarter of 2011. Strong sales growth of key products helped offset the impact of the August 2012 loss of market exclusivity for SINGULAIR (montelukast sodium) in the United States.

The following table reflects sales of the company's top pharmaceutical products, as well as total sales of animal health and consumer care products.
   

 

$ in millions
 

Fourth Quarter 2012
 

Fourth Quarter 2011
 

Change
 

Year Ended Dec. 31, 2012
 

Year Ended Dec. 31, 2011
 

 

 

Change
Total Sales   $11,738   $12,294   -5%   $47,267   $48,047   -2%
Pharmaceutical   10,085   10,755   -6%   40,601   41,289   -2%
JANUVIA   1,134   960   18%   4,086   3,324   23%
SINGULAIR   480   1,461   -67%   3,853   5,479   -30%
ZETIA   676   640   6%   2,567   2,428   6%
REMICADE   549   511   8%   2,076   2,667   -22%
VYTORIN   435   475   -8%   1,747   1,882   -7%
JANUMET   452   386   17%   1,659   1,363   22%
GARDASIL   442   274   61%   1,631   1,209   35%
ISENTRESS   381   387   -2%   1,515   1,359   11%
COZAAR/HYZAAR   315   427   -26%   1,284   1,663   -23%
PROQUAD, M-M-R II and VARIVAX   306   276   11%   1,273   1,202   6%
Animal Health   898   868   3%   3,399   3,253   4%
Consumer Care   395   361   9%   1,952   1,840   6%
Other Revenues   360   310   16%   1,315   1,666   -21%

Pharmaceutical Revenue Performance

Fourth-quarter pharmaceutical sales declined 6 percent to $10.1 billion, including a 1 percent negative impact due to foreign exchange. Strong sales growth for JANUVIA (sitagliptin), GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], ZOSTAVAX (zoster vaccine live) and JANUMET (sitagliptin/metformin hydrochloride) partially offset the expected declines in sales of SINGULAIR, COZAAR (losartan potassium) and HYZAAR (losartan potassium and hydrochlorothiazide).

3 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,511.08 -172.50 -0.98%
S&P 500 2,048.91 -19.85 -0.96%
NASDAQ 4,916.8650 -75.0750 -1.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs